1.             Introduction. 9

1.1       Study Scope. 9

1.2       The Insight Partners Research Report Guidance. 9

1.3       Market Segmentation

1.3.1        US Prostate Cancer Nuclear Medicine Diagnostics Market – By Type

1.3.2        US Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product

2.             Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             US Prostate Cancer Nuclear Medicine Diagnostics Market Landscape

4.1       Market Overview

4.2       PEST Analysis

4.2.1        US: PEST Analysis

4.3       Expert Opinion

5.             US Prostate Cancer Nuclear Medicine Diagnostics Market  Key Market Dynamics

5.1       Market Drivers

5.1.1        Rising Prevalence of Prostate Cancer

5.1.2        Growth Of Innovative Radiopharmaceuticals

5.2       Key Market Restraints

5.2.1        Strict Guidelines for Storage, Production, & Use of Radiopharmaceuticals

5.3       Key Market Opportunities

5.3.1        Rising Demand For Precise Diagnostic Methods

5.4       CURRENT TREND

5.4.1        Use of Hybrid Nuclear Medicine For Treatment

5.5       Impact analysis

6.             Prostate Cancer Nuclear Medicine Diagnostics – US Market Analysis

6.1       US Prostate Cancer Nuclear Medicine Diagnostics Market Overview

6.2       Market Positioning of Key Players

7.             US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type

7.1       Overview

7.2       US Prostate Cancer Nuclear Medicine Diagnostics Market, By Type (2019 and 2027)

7.2.1.1      US Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2027 (USD Million)

7.3       SPECT

7.3.1        Overview

7.3.2        SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

7.4       PET

7.4.1        Overview

7.4.2        PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

8.             US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product

8.1       Overview

8.2       US Prostate Cancer Nuclear Medicine Diagnostics Market, By Product (2019 and 2027)

8.2.1.1      US Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2027  (USD Million)

8.3       F-18

8.3.1        Overview

8.3.2        F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

8.4       C-11

8.4.1        Overview

8.4.2        C-11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

8.5       Ga68-PSMA

8.5.1        Overview

8.5.2        Ga68-PSMA: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)

9.             US Prostate Cancer Nuclear Medicine Diagnostics Market Industry Landscape

9.1       Overview

9.2       Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market, 2017-2020

9.3       Inorganic Growth Strategies

9.3.1        Overview

9.4       Organic Growth Strategies

9.4.1        Overview

10.          COMPANY PROFILES

10.1    Blue Earth Diagnostics Limited

10.1.1     Key Facts

10.1.2     Business Description

10.1.3     Products and Services

10.1.4     Financial Overview

10.1.5     SWOT Analysis

10.1.6     Key Developments

10.2    Progenics Pharmaceuticals, Inc.

10.2.1     Key Facts

10.2.2     Business Description

10.2.3     Products and Services

10.2.4     Financial Overview

10.2.5     SWOT Analysis

10.2.6     Key Developments

10.3    Curium

10.3.1     Key Facts

10.3.2     Business Description

10.3.3     Products and Services

10.3.4     Financial Overview

10.3.5     SWOT Analysis

10.3.6     Key Developments

10.4    Telix Pharmaceuticals Ltd.

10.4.1     Key Facts

10.4.2     Business Description

10.4.3     Products and Services

10.4.4     Financial Overview

10.4.5     SWOT Analysis

10.4.6     Key Developments

10.5    NCM-USA LLC

10.5.1     Key Facts

10.5.2     Business Description

10.5.3     Products and Services

10.5.4     Financial Overview

10.5.5     SWOT Analysis

10.5.6     Key Developments

10.6    ABX advanced biochemical compounds GmbH

10.6.1     Key Facts

10.6.2     Business Description

10.6.3     Products and Services

10.6.4     Financial Overview

10.6.5     SWOT Analysis

10.6.6     Key Developments

10.7    Jubilant Radiopharma

10.7.1     Key Facts

10.7.2     Business Description

10.7.3     Products and Services

10.7.4     Financial Overview

10.7.5     SWOT Analysis

10.7.6     Key Developments

10.8    Lantheus Medical Imaging, Inc.

10.8.1     Key Facts

10.8.2     Business Description

10.8.3     Products and Services

10.8.4     Financial Overview

10.8.5     SWOT Analysis

10.8.6     Key Developments

10.9    Advanced Accelerator Applications (Novartis AG)

10.9.1     Key Facts

10.9.2     Business Description

10.9.3     Products and Services

10.9.4     Financial Overview

10.9.5     SWOT Analysis

10.9.6     Key Developments

10.10 Theragnostics

10.10.1   Key Facts

10.10.2   Business Description

10.10.3   Products and Services

10.10.4   Financial Overview

10.10.5   SWOT Analysis

10.10.6   Key Developments

11.          Appendix

11.1    About The Insight Partners

11.2    Word Index

LIST OF TABLES

Table 1.            US Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2027  (USD Million)

Table 2.            US Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2027 (USD Million)

Table 3.            Recent Inorganic Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market

Table 4.            Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics market

Table 5.            List of Abbreviation

LIST OF FIGURES

Figure 1.          US Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

Figure 2.          US Prostate Cancer Nuclear Medicine Diagnostics Market Overview

Figure 3.          PET is Expected to Show Remarkable Growth During Forecast Period

Figure 4.          Ga68-PSMA is Expected to Have Fastest Growth During Forecast Period

Figure 5.          Prostate Cancer Nuclear Medicine Diagnostics Market, Industry Landscape

Figure 6.          US: PEST Analysis

Figure 7.          Expert Opinion

Figure 8.          US Prostate Cancer Nuclear Medicine Diagnostics Market – Impact Analysis of Drivers and Restraints

Figure 9.          Overview of US Prostate Cancer Nuclear Medicine Diagnostics Market

Figure 10.       Market Positioning Of Key Players In US Prostate Cancer Nuclear Medicine Diagnostics Market

Figure 11.       US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Share, by Type (2019 and 2027)

Figure 12.       SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

Figure 13.       PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)

Figure 14.       US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Share, by Product (2019 and 2027)

Figure 15.       F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)

Figure 16.       C-11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)

Figure 17.       Ga68-PSMA: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027  (US$ Million)

Figure 18.       Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market, 2017-2020